CONTEXT: Pseudohypoaldosteronism type 1 (PHA1) is a rare salt-wasting syndrome. Mutations in the NR3C2 gene coding for the mineralocorticoid receptor (MR) cause autosomal dominant PHA1. OBJECTIVE: Our objective was to reveal the cause of renal salt loss in six PHA1 patients and analyze the mutants' functional impact on MR function. DESIGN: Our study included the following: clinical and hormonal characterization of the patients' phenotype, analysis of the NR3C2 gene, determination of receptor affinities to aldosterone and the transcriptional activation abilities of the MR mutants, investigation of subcellular translocation using fluorescence-labeled MR, and studying changes in mutant receptor conformation with proteolysis experiments and three-dimensional modeling. RESULTS: Six heterozygous NR3C2 mutations were detected. One frameshift mutation (c.1131dupT) has been reported previously. The second frameshift mutation (c.2871dupC), which has only recently been reported by our group, showed no aldosterone binding and no transactivation because of a major change in receptor conformation. Two novel nonsense mutations generate a truncated receptor protein. Two missense mutations differently affect MR function. S818L was reported recently without complete in vitro data. S818L does not bind aldosterone or activate transcription or translocate into the nucleus. A major displacement of several residues involved in aldosterone binding was PHA1 causing. The novel E972G mutation showed a significantly lower ligand-binding affinity and only 9% of wild-type transcriptional activity caused by major changes in receptor conformation. CONCLUSIONS: Our data on six mutations extend the spectrum of PHA1-causing NR3C2 gene mutations. Studying naturally occurring mutants helps to clarify their pathogenicity and to identify crucial residues for MR structure and function.
CONTEXT: Pseudohypoaldosteronism type 1 (PHA1) is a rare salt-wasting syndrome. Mutations in the NR3C2 gene coding for the mineralocorticoid receptor (MR) cause autosomal dominant PHA1. OBJECTIVE: Our objective was to reveal the cause of renal salt loss in six PHA1patients and analyze the mutants' functional impact on MR function. DESIGN: Our study included the following: clinical and hormonal characterization of the patients' phenotype, analysis of the NR3C2 gene, determination of receptor affinities to aldosterone and the transcriptional activation abilities of the MR mutants, investigation of subcellular translocation using fluorescence-labeled MR, and studying changes in mutant receptor conformation with proteolysis experiments and three-dimensional modeling. RESULTS: Six heterozygous NR3C2 mutations were detected. One frameshift mutation (c.1131dupT) has been reported previously. The second frameshift mutation (c.2871dupC), which has only recently been reported by our group, showed no aldosterone binding and no transactivation because of a major change in receptor conformation. Two novel nonsense mutations generate a truncated receptor protein. Two missense mutations differently affect MR function. S818L was reported recently without complete in vitro data. S818L does not bind aldosterone or activate transcription or translocate into the nucleus. A major displacement of several residues involved in aldosterone binding was PHA1 causing. The novel E972G mutation showed a significantly lower ligand-binding affinity and only 9% of wild-type transcriptional activity caused by major changes in receptor conformation. CONCLUSIONS: Our data on six mutations extend the spectrum of PHA1-causing NR3C2 gene mutations. Studying naturally occurring mutants helps to clarify their pathogenicity and to identify crucial residues for MR structure and function.
Authors: Bei Sun; Bindu Chamarthi; Jonathan S Williams; Alexander W Krug; Jessica Lasky-Su; Benjamin A Raby; Paul N Hopkins; Xavier Jeunemaitre; Claudio Ferri; Gordon H Williams Journal: J Clin Endocrinol Metab Date: 2012-06-20 Impact factor: 5.958
Authors: May E Montasser; Donfeng Gu; Jing Chen; Lawrence C Shimmin; Charles Gu; Tanika N Kelly; Cashell E Jaquish; Treva Rice; Dabeeru C Rao; Jie Cao; Jichun Chen; De-Pei Liu; Paul K Whelton; Jiang He; James E Hixson Journal: Am J Hypertens Date: 2011-06-09 Impact factor: 2.689
Authors: F L Fernandes-Rosa; A C Bueno; R Molina de Souza; M de Castro; J Ernesto dos Santos; M C Foss; M-C Zennaro; H Bettiol; M A Barbieri; S R Antonini Journal: J Endocrinol Invest Date: 2009-12-01 Impact factor: 4.256
Authors: Se Eun Lee; Yun Hye Jung; Kyoung Hee Han; Hyun Kyung Lee; Hee Gyung Kang; Il Soo Ha; Yong Choi; Hae Il Cheong Journal: Korean J Pediatr Date: 2011-02-28
Authors: Mohammed Ayed Huneif; Ziyad Hamad Alhazmy; Anas M. Shoomi; Mohammed A. Alghofely; Humariya Heena; Aziza M. Mushiba; Abdulhamid AlSaheel Journal: J Clin Res Pediatr Endocrinol Date: 2021-04-08